Regeneron (REGN) Tops Q3 EPS by 40c; EYLEA Sales Rose 16%
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.13, $0.40 better than the analyst estimate of $2.73. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.29 billion.
EYLEA sales rose 16% to $854 million, from $734 million in Q315.
2016 Financial Guidance(3)
The Company's updated full year 2016 financial guidance consists of the following components:
EYLEA U.S. net product sales
23% - 25% growth over 2015
(previously 20% - 25% growth over 2015)
Sanofi reimbursement of Regeneron commercialization-related expenses
$310 million - $335 million
(previously $310 million - $340 million)
Non-GAAP unreimbursed R&D(2) (4)
$945 million - $975 million
(previously $970 million - $1.01 billion)
Non-GAAP SG&A(2) (4)
$965 million - $995 million
(previously $980 million - $1.02 billion)
Effective tax rate
29% - 33%
(previously 33% - 41%)
$480 million - $510 million
(previously $480 million - $530 million)
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs (GS) Tops Q4 EPS by 26c
- ASML Holdings (ASML) Reports Q4 EPS of EUR1.23
- Pinnacle Financial Partners (PNFP) Tops Q4 EPS by 2c
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!